Vasopressin formulations for use in treatment of hypotension
DC CAFCFirst Claim
Patent Images
1. A method of increasing blood pressure in a human in need thereof, the method comprising:
- a) providing a pharmaceutical composition for intravenous administration comprising;
i) from about 0.01 mg/mL to about 0.07 mg/mL of vasopressin or a pharmaceutically-acceptable salt thereof;
ii) acetic acid; and
iii) water,wherein the pharmaceutical composition has a pH of 3.8;
b) storing the pharmaceutical composition at 2-8°
C. for at least 4 weeks; and
c) intravenously administering the pharmaceutical composition to the human,wherein the administration provides to the human from about 0.01 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute to about 0.1 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute,wherein the human is hypotensive,wherein the pharmaceutical composition exhibits less than about 5% degradation after storage at 2-8°
C. for about four weeks.
5 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
199 Citations
20 Claims
-
1. A method of increasing blood pressure in a human in need thereof, the method comprising:
-
a) providing a pharmaceutical composition for intravenous administration comprising;
i) from about 0.01 mg/mL to about 0.07 mg/mL of vasopressin or a pharmaceutically-acceptable salt thereof;
ii) acetic acid; and
iii) water,wherein the pharmaceutical composition has a pH of 3.8; b) storing the pharmaceutical composition at 2-8°
C. for at least 4 weeks; andc) intravenously administering the pharmaceutical composition to the human, wherein the administration provides to the human from about 0.01 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute to about 0.1 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute, wherein the human is hypotensive, wherein the pharmaceutical composition exhibits less than about 5% degradation after storage at 2-8°
C. for about four weeks. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification